Drug Marketing

WASHINGTON – The Orphan Drug Act “unambiguously entitles” Eagle Pharmaceuticals a seven-year period of marketing exclusivity for a drug that treats leukemia and non-Hodgkin lymphoma, the U.S. Court of Appeals for the D.C. Circuit ruled.

%d bloggers like this: